14,15-Didehydrovincanmine






Names

    • 14,15-dehydrovincamine
    • CHEMBL4761192
    • 17,18-Didehydrovincamine
    • CHEBI:141861
    • DTXSID60186455
    • Eburnamenine-14-carboxylic acid, 17,18-didehydro-14,15-dihydro-14-hydroxy-, methyl ester, (3alpha,14beta,16alpha)-
    • 14,15-Didehydrovincanmine
    • 32790-09-3
    • 17,18-Dehydrovincamine
    • methyl (15R,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18),13-pentaene-17-carboxylate

Attributes

  • Canonical SMILES

    CC[C@]1([C@]2([H])N3CCC4=C2N([C@@](C(OC)=O)(C1)O)C5=C4C=CC=C5)C=CC3[H]

  • InChI

    InChI=1S/C21H24N2O3/c1-3-20-10-6-11-22-12-9-15-14-7-4-5-8-16(14)23(17(15)18(20)22)21(25,13-20)19(24)26-2/h4-8,10,18,25H,3,9,11-13H2,1-2H3/t18-,20+,21+/m1/s1

  • Molecule Class: Alkaloids
  • TPSA: 54.7
  • #RotBonds: 2
  • MW: 352.434
  • HBD: 1
  • HBA: 5
  • logP: 2.7285000000000013
  • Chemical Formula: C21H24N2O3


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. bovina China, Vietnam 3036760 Cai20150423

External Databases


References

  • Vincan- and eburnan-type alkaloids from Tabernaemontana bovina and their hypoglycemic activity. Phytochemistry, 2021 (PMID 34218044).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Hypoglycemic

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.8
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.7
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -2.47
    Distribution Blood-Brain Barrier (Central Nervous System) -2.31
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.1
    Plasma Protein Binding 53.09
    Steady State Volume of Distribution 2.83
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Substrate
    CYP 2D6 Inhibitor Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 9.58
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 0.84
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.26
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 5.65
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -7.02
    Rat (Acute) 2.87
    Rat (Chronic Oral) 1.61
    Fathead Minnow 4.08
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Toxic
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 426.22
    Hydration Free Energy -6.64
    Log(D) at pH=7.4 2.67
    Log(P) 2.83
    Log S -2.75
    Log(Vapor Pressure) -8.45
    Melting Point 200.3
    pKa Acid 8.17
    pKa Basic 6.22